

ARTICLE

Human balanced translocation and mouse gene inactivation implicate *Basonuclin 2* in distal urethral development

Elizabeth J Bhoj¹, Purita Ramos¹, Linda A Baker², Nicholas Cost², Agneta Nordenskjöld³, Frederick F Elder⁴, Steven B Bleyl⁵, Neil E Bowles⁵, Cammon B Arrington⁵, Brigitte Delhomme⁶, Amandine Vanhoutteghem⁶, Philippe Djian^{*6} and Andrew R Zinn^{*1}

We studied a man with distal hypospadias, partial anomalous pulmonary venous return, mild limb-length inequality and a balanced translocation involving chromosomes 9 and 13. To gain insight into the etiology of his birth defects, we mapped the translocation breakpoints by high-resolution comparative genomic hybridization (CGH), using chromosome 9- and 13-specific tiling arrays to analyze genetic material from a spontaneously aborted fetus with unbalanced segregation of the translocation. The chromosome 13 breakpoint was ~400 kb away from the nearest gene, but the chromosome 9 breakpoint fell within an intron of *Basonuclin 2* (*BNC2*), a gene that encodes an evolutionarily conserved nuclear zinc-finger protein. The *BNC2/Bnc2* gene is abundantly expressed in developing mouse and human periurethral tissues. In all, 6 of 48 unrelated subjects with distal hypospadias had nine novel nonsynonymous substitutions in *BNC2*, five of which were computationally predicted to be deleterious. In comparison, two of 23 controls with normal penile urethra morphology, each had a novel nonsynonymous substitution in *BNC2*, one of which was predicted to be deleterious. *Bnc2*^{-/-} mice of both sexes displayed a high frequency of distal urethral defects; heterozygotes showed similar defects with reduced penetrance. The association of *BNC2* disruption with distal urethral defects and the gene's expression pattern indicate that it functions in urethral development.

European Journal of Human Genetics (2011) 19, 540–546; doi:10.1038/ejhg.2010.245; published online 2 February 2011

Keywords: basonuclin 2; hypospadias; birth defects; urethra

INTRODUCTION

Hypospadias, when the urethral orifice is located on the ventral aspect of the penis, is found in 0.7% of live births.¹ Although previous studies have suggested that the majority of cases are sporadic and multifactorial,² multiple families have been described with isolated hypospadias and apparent autosomal dominant inheritance.³ Genes involved in the etiology of hypospadias and their interactions with environmental factors were recently reviewed.⁴ Androgen signaling is crucial to normal penile development, and most known genetic causes of hypospadias involve defects in androgen signaling. For instance, mutations in the 5- α reductase gene (*SRD5A2*) or the androgen receptor gene (*AR*) may cause severe hypospadias, usually in conjunction with other genital malformations.^{5–7} Additionally, mutations in *MAMLD1* cause a rare X-linked form of the disorder.⁸ *MAMLD1* contains an SF1 binding site and transactivates the noncanonical Notch target gene *Hes3* to augment testosterone production in Leydig cells.⁹ Other genes that are involved in penile or urethral patterning have been linked to human hypospadias, including *HOXA13*, mutations of which cause hand-foot-genital syndrome.^{10,11}

Basonuclin 2 (*BNC2*) is a gene of unknown function that is evolutionarily conserved in vertebrates.¹² The predicted BNC2 protein is about 1100 amino acids in length and contains a nuclear localization signal and three zinc-finger motifs,^{13,14} with a similar overall structure to Basonuclin 1 (*BNC1*), a protein found in keratinocytes¹⁵ and germ cells¹⁶ that acts as a transcription factor for ribosomal RNA^{17,18} and possibly also RNA polymerase II-dependent genes.¹⁹ *BNC1* and *BNC2* show nonoverlapping patterns of expression, and BNC2 but not BNC1 localizes to nuclear speckles, suggesting that BNC2 functions in mRNA processing.²⁰ *Bnc2*^{-/-} knockout mice die perinatally, with cleft palate and other craniofacial abnormalities.²¹

We serendipitously identified a man with a *de novo* balanced 9;13 translocation and distal hypospadias, partial anomalous pulmonary venous return (PAPVR) and mild lower-limb length inequality. We used a novel array comparative genomic hybridization (CGH) approach to characterize the translocation breakpoints, taking advantage of the availability of genetic material from a spontaneously aborted fetus he fathered with unbalanced segregation of the translocation. The CGH results allowed us to rapidly determine that *BNC2* is a candidate gene for PAPVR and hypospadias. To corroborate the role

¹McDermott Center for Human Growth and Development and Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA; ²Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; ³Department of Pediatric Surgery, Astrid Lindgren Children's Hospital Karolinska University Hospital, SE-141 86 and Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; ⁴Genzyme Corporation, 10421 University Center Drive Suite 100, Tampa, FL, USA; ⁵Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA; ⁶Unité de Régulation de la Transcription et Maladies Génétiques, Centre National de la Recherche Scientifique/Université Paris Descartes, Paris, France

*Correspondence: Professor P Djian, Centre Universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France. Tel: +33 1 42 86 22 72; Fax: +33 1 42 60 55 37; E-mail: philippe.djian@parisdescartes.fr or Dr AR Zinn, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8591 USA. Tel: +214 648 1600; Fax: +214 648 1666; E-mail: andrew.zinn@utsouthwestern.edu

Received 3 August 2010; revised 18 November 2010; accepted 9 December 2010; published online 2 February 2011

of *BNC2* in these birth defects, we screened additional subjects with APVR or hypospadias for *BNC2*-coding mutations and carefully analyzed the phenotype of *Bnc2*-knockout mice.

MATERIALS AND METHODS

Oligonucleotide array CGH

Genomic DNA was purified from cultured cells from products of conception (POC) by standard methods. CGH was performed by Nimblegen Systems Inc. (Madison, WI, USA) using chromosome-specific tiling arrays containing 385 000 isothermal 50–75-mer oligonucleotide probes and pooled normal human male reference DNA (Promega, Madison, WI, USA). The mean probe density was one probe per 255 bp for chromosome 9 (Catalog No. B3740001-00-01) and one probe per 225 bp for chromosome 13 (Catalog No. B3744001-00-01).

Fluorescence *in situ* hybridization (FISH)

Metaphase chromosomes were prepared from either PHA-stimulated whole-blood lymphocytes or EBV-immortalized lymphoblasts. BAC clones were purchased from BACPAC resources (Oakland, CA, USA). BAC DNAs were isolated using the BACMAX DNA isolation kit (Epicentre, Madison, WI, USA), labeled with Spectrum Orange according to the manufacturer's instructions (Vysis, Downers Grove, IL, USA), precipitated, resuspended in LSI/WCP hybridization buffer (Vysis), and hybridized to slides overnight at 37°C. Washed and dehydrated slides were counterstained with DAPI II (Vysis) and visualized with an Olympus BX-61 fluorescence microscope. Images were captured with a CCD camera and Cytovision software (Applied Imaging, San Jose, CA, USA).

Quantitative RT-PCR

Multiple human fetal tissue RNAs were purchased from Clontech Laboratories (Mountain View, CA, USA, Catalog No. 636747). Lymphoblastoid cell RNAs were isolated using Tripure (Roche, Indianapolis, IN, USA), and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to the manufacturers' protocols. Transcripts of *BNC2*, *LMO7* and a control gene (*cyclophilin A*) were measured by real-time PCR using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) Hs00214187_m1 (*BNC2* exons 5 and 6), Hs00417700_m1 (*BNC2* exons 3 and 4), Hs00245600_m1 (*LMO7*) and *cyclophilin A* (Catalog No. 4310883E). The *BNC2* and *LMO7* probes contained a 6-carboxy-fluorescein phosphoramidite (FAM dye) label at the 5'-end and were designed to hybridize across intron/exon junctions. The *cyclophilin A* control probe was labeled with VIC dye and used in multiplex with the *BNC2* or *LMO7* probes. We used cDNA derived from human skeletal muscle RNA (Clontech Laboratories) for calibration and generation of standard curves. Reactions were performed in triplicate. Samples with replicate coefficient of variation >20% were repeated.

Allelic expression

The 5'-untranslated region (UTR) of *LMO7* was amplified with primers 5'-TCAGATAATCTTAAGGCTGTTGG-3' and 5'-TTTCCTCATGAGCAGTG TGC-3'. The 5'-UTR of *BNC2* was amplified with primers 5'-CTTTTCAAA GTTGCTGAAATAAAA-3' and 5'-TTGCATTTAATGGCCTCAGA-3'. Genomic PCR products from the proband were sequenced and a heterozygous SNP identified in each gene (*LMO7*: rs9565177; *BNC2*: rs1999032). RT-PCR products were amplified from DNase-treated cDNA isolated from lymphoblastoid cells carrying the balanced translocation as described above, and sequenced. Control reactions omitting reverse transcriptase were performed to rule out amplification of contaminating genomic DNA. Electropherograms of genomic and cDNA sequences were compared to determine whether both alleles of *LMO7* and *BNC2* were expressed.

Mutation screening

Informed consent/assent for this study was obtained from human subjects under protocols approved by the University of Texas Southwestern Medical Center and the University of Utah Institutional Review Boards. Genomic DNA was extracted from whole blood of the proband and forty other subjects with

surgically-repaired APVR. *BNC2* exons 1, 2, 2a, 3, 4, 5 and 6 (numbered according to ref.12) were PCR-amplified using primers designed with Primer-3 (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3>) and both strands sequenced with the same primers. Primer sequences are available upon request. Sequence data were analyzed using Seqman (DNASTar, Madison, WI, USA). *BNC2* coding exons from subjects with hypospadias and controls with normal penile urethral anatomy were analyzed in a similar manner by Polymorphic DNA Technologies, Inc. (Alameda, CA, USA). Missense substitutions were analyzed by SIFT²² using the web site <http://sift.jcvi.org/>.

Mouse studies

Animal studies were approved by the Université Paris Descartes Animal Use Committee. For X-gal staining of sections, newborns were snap frozen in OCT (Miles, Elkhart, IN, USA) and isopentane, and cut with a cryomicrotome at 7 µm. Sections were then fixed in formaldehyde/glutaraldehyde (2%:0.2%), incubated in the presence of X-gal overnight at 37°C and counterstained with hematoxylin/eosin. Genotype and sex were determined by PCR.

RESULTS

The proband (Supplementary Figure 1) was a healthy 33 year old man with unrepaired mild coronal hypospadias and PAPVR that required surgical repair at age 23. The right upper and right middle pulmonary veins drained anomalously to the superior vena cava. He also had mild lower-limb length inequality treated with a shoe lift, but no other medical problems. His spouse suffered two miscarriages; cytogenetic study of the POC from the second miscarriage revealed an unbalanced 9;13 translocation, karyotype 46,XX,der(9)t(9;13)(p22;q22). Further testing showed that the proband carried a *de novo* balanced 9;13 translocation (Supplementary Figure 1) that was not transmitted to his healthy daughter.

We assumed that the molecular chromosomal breakpoints were the same in the proband with the balanced translocation as in the POC with the unbalanced translocation. Taking advantage of the availability of POC cells, we performed tiling array CGH using chromosome 9- and 13-specific oligonucleotide arrays in order to fine-map the breakpoints. The CGH results confirmed that the POC was trisomic for 13q22-qter (Figure 1a) and monosomic for 9pter-p22 (Figure 1b). Breakpoints were mapped from the CGH data to a 3 kb interval of chromosome 9 (chr9:16 508 500–16 511 500, GRCh37/hg19 genome assembly) and a 4 kb interval of chromosome 13 (chr13:76 839 999–76 843 999).

Both breakpoints were confirmed using FISH with chromosome 9 and 13 BAC clones. Both clones consistently showed two signals in the expected locations when hybridized to normal control metaphases. In contrast, each probe consistently showed three signals, one with normal intensity and two with reduced intensity, when hybridized to the proband's metaphases (Figure 1). The FISH results confirmed that the breakpoints were the same in the proband and the POC, and ruled out a sizable cryptic deletion at either junction.

The chromosome 13 breakpoint did not disrupt any known gene. It was ~400 kb downstream of the nearest gene, *LMO7*, which encodes a putative transcriptional regulator containing PDZ and LIM protein-protein interaction domains. The chromosome 9 breakpoint fell within a large intron of the *BNC2*, which encodes a zinc-finger protein gene of unknown function.¹⁴ *BNC2* shows a highly complex pattern of alternative splicing, promoters and polyadenylation sites, and encodes a plethora of predicted proteins, some of which share no amino acids with each other.¹² However, nearly all *BNC2* transcripts contain exons 5 and 6 (numbered according to ref. 12). Both of these exons are required for the function of the protein as they encode all the important features of the protein including the six zinc fingers and the nuclear localization signal. As the breakpoint disrupts *BNC2*




Figure 1 Array CGH and FISH mapping of translocation breakpoints for chromosomes 13 (**a**) and 9 (**b**). CGH graphs show coordinates from NCBI 36.1 (hg18) genome assembly (X axis); \log_2 relative hybridization signal intensity versus control (Y axis). Arrows on metaphase spreads point to hybridization signals (red).

between exons 4 and 5, it is predicted to cause a null mutation. No *BNC2* coding mutations were identified in the proband, whose phenotype thus appeared likely to result from *BNC2* haploinsufficiency.

The tissue distribution of *LMO7* mRNA and two major *BNC2* transcripts was assessed by quantitative RT-PCR using human adult

and fetal multiple tissue RNA panels (Supplementary Figure 2). In adult tissues, *BNC2* was especially prevalent in the uterus, with expression also observed in kidney, lung, prostate, testes and trachea. The highest levels of *LMO7* were observed in heart, lung and skeletal muscle. In fetal tissues, *BNC2* transcripts containing exons 3 and 4 were highly expressed in both heart and penis; transcripts containing exons 5 and 6 were also enriched in fetal penis, whereas *LMO7* also showed the highest levels in fetal heart and penis.

To determine if the translocation perturbed either *LMO7* or *BNC2* expression, we identified a heterozygous SNP in the 5'-UTR of each gene. RT-PCR products from lymphoblastoid cells carrying the balanced translocation were heterozygous for these SNPs, with approximately equal peak heights (Figure 2a), similar to that of sequences of genomic PCR products. These data indicate that, at least in lymphoblastoid cell lines, *LMO7* or *BNC2* alleles on both the normal and the derivative chromosomes were transcribed at roughly equal levels, although presumably the *BNC2* transcript(s) from the derivative-9 chromosome lack exons 5 and 6. Additionally, the *LMO7* mRNA level in immortalized lymphoblasts from the proband was within the range demonstrated by the normal controls (Figure 2b). Although we were able to amplify trace amounts of biallelic *BNC2* transcripts in lymphoblastoid cells from the proband, the level of expression in this cell type was not sufficient for quantitation.

To corroborate a role for *BNC2* in birth defects, we sequenced the major *BNC2* coding exons (1, 2, 2a, 3–6; ref.12) in the proband and 40 unrelated subjects with surgically repaired APVR (Table 1). None of the males in this sample had hypospadias. Two novel nonsynonymous substitutions were found in exon 5: D760E was found in a subject with partial APVR and an ASD (APVR7), and L414V was found in a subject with total APVR (APRV36). The aspartic acid residue in the first substitution is evolutionarily conserved among *BNC2* orthologs but not between *BNC2* and its paralog, *BNC1*.¹⁴ This residue is not within any known functional protein domain. The second substitution alters a leucine that is conserved among *BNC2* orthologs and its *BNC1* paralog, but also does not fall within any known functional domains. This subject's parents, both without known medical conditions, were studied and his mother was found to carry the same substitution.




Figure 2 (a) RT-PCR and sequencing demonstrating biallelic expression of *LMO7* and *BNC2* in lymphoblastoid cells from the proband. K=T/G; Y=C/T. (b) *LMO7* and *BNC2* expression in lymphoblastoid cell lines from proband vs normal male controls.

Table 1 Novel nonsynonymous *BNC2* sequence variations among subjects with anomalous pulmonary venous return (n=40), hypospadias (n=48) or controls (n=23)

ID	Phenotype	Subject		Nonsynonymous variation				SIFT analysis	
		Sex	Race/ethnicity	Genomic	cDNA	Exon	Protein	Predicted effect	Score
APVR7	PAPVR, ASD	F	Caucasian/hispanic	chr9:16435912	c.2280T>G	5	p.D760E	Tolerated	0.49
APVR15	PAPVR (scimitar syndrome)	F	Caucasian/nonhispanic	chr9:16419519	c.2768C>T	6	p.A923V	Tolerated	0.1
APVR33	TAPVR	M	Caucasian/nonhispanic	chr9:16419519	c.2768C>T	6	p.A923V	Tolerated	0.1
APVR36	TAPVR	F	Caucasian/nonhispanic	chr9:16436952	c.1240C>G	5	p.L414V	Tolerated	0.37
APVR38	TAPVR	F	Caucasian/nonhispanic	chr9:16419519	c.2768C>T	6	p.A923V	Tolerated	0.1
H151P	Hypospadias	M	Caucasian/nonhispanic	chr9:16437276	c.916C>G	5	p.P306A	Damaging	0.04
HS013	Hypospadias	M	Caucasian/nonhispanic	chr9:16436456	c.1735C>T	5	p.P579L	Damaging	0
HS038	Hypospadias	M	Caucasian/nonhispanic	chr9:16419519	c.2768C>T	6	p.A923V	Tolerated	0.1
HS071	Hypospadias	M	Caucasian/nonhispanic	chr9:16436952	c.1240C>G	5	p.L414V	Tolerated	0.37
H160P	Hypospadias	M	Caucasian/nonhispanic	chr9:16552742	c.455A>G	4	p.Q152R	Tolerated	0.46
H160P	Hypospadias	M	Caucasian/nonhispanic	chr9:16437473	c.719A>G	5	p.E240G	Damaging	0
H160P	Hypospadias	M	Caucasian/nonhispanic	chr9:16437345	c.847A>G	5	p.R283G	Damaging	0
H197P	Hypospadias	M	African-american	chr9:16419519	c.2768C>T	6	p.A923V	Tolerated	0.1
N200P	Control	M	Caucasian/hispanic	chr9:16436324	c.1868C>A	5	p.P623H	Damaging	0.04
N203P	Control	M	Caucasian/nonhispanic	chr9:16436391	c.1802A>G	5	p.I601V	Tolerated	1

Abbreviations: ASD, atrial septal defect; PAPVR, partial anomalous pulmonary venous return; TAPVR, total anomalous pulmonary venous return. Variations are referenced to genome assembly GRCh37/hg19, ENSEMBL transcript ENST00000380672 and protein ENSP00000370047, and are described according to Human Genome Variation Society guidelines.³⁰

An additional novel nonsynonymous substitution, A923V, was found in exon 6 in three subjects, one with PAPVR and two with TAPVR. It changes an alanine residue conserved among *BNC2* orthologs, but not between *BNC2* and *BNC1*, and is also not in any known domains. None of the nonsynonymous substitutions in APVR subjects were predicted to be deleterious by SIFT.²²

We next screened for *BNC2* coding variations in 48 subjects with distal hypospadias *vs* 23 controls with normal penile urethra anatomy. The results (Table 1) showed eight heterozygous novel nonsynonymous substitutions in six hypospadias subjects (one subject had three nonsynonymous substitutions) *vs* two novel nonsynonymous substitutions in two controls (6/48 (12.5%) *vs* 2/23 (8.7%), $P=NS$). Four nonsynonymous substitutions in three hypospadias subjects were predicted to be deleterious by SIFT, but so was one of the nonsynonymous substitutions present in a control. Two of the substitutions in hypospadias subjects, L414V and A923V, were also found in APVR subjects.

We then analyzed *Bnc2* expression in the penis and urethra of *bnc2*^{+/-} and *bnc2*^{-/-} mice.²¹ These mice carry a *lacZ* gene inserted into a large *Bnc2* intron and express β -galactosidase under the control of the *Bnc2* promoter. Frozen sections of male *bnc2*^{+/-} newborns were stained for β -gal activity using X-gal as a chromogenic substrate.




Figure 3 β -galactosidase staining (blue) of heterozygous mice carrying a *lacZ* gene integrated in the *Bnc2* locus showing abundant expression in periurethral penile tissues. (a) Transverse section of newborn male mouse through lower abdomen. (b) Enlargement of the penis boxed in (a).

Transverse sections of the entire mouse in the lower abdominal region showed that *bnc2-lacZ* expression is highest in the developing penis (Figure 3a). β -gal activity is specific to the cells of the preputial lamella and in a zone of mesenchymal cells just exterior to the corpus spongiosum and just exterior to the condensed mesenchyme of the future os penis (Figure 3b). As homozygous mutant mice die soon after birth, examination was limited to newborns, a high proportion of which showed the presence of a cleft in the ventral part of the external genitalia in both males and females (Figure 4a). This was presumably because of the inability of the urethral folds to fuse at the ventral midline. Male phallic size was normal in both genotypes. Heterozygous mice also showed a urethral defect, but with reduced penetrance and severity compared with *bnc2*^{-/-} mice (Figure 4a; Table 2). Dye injections into the bladder demonstrated patency of the urethra, which terminated as a hypospadiac urethral meatus in homozygotes (Figure 4b). No obvious cardiac defects were seen in these mice, and the developing heart and surrounding vasculature did not clearly stain for β -gal activity.

DISCUSSION

Disease-associated balanced translocations are powerful tools to identify developmental genes.²³ Although the availability of the human genome sequence and BAC clones for any region of interest have greatly facilitated mapping studies, characterizing a translocation breakpoint beyond the limit of resolution of FISH remains laborious. In this report, we demonstrate how array CGH, another technological innovation enabled by the human genome sequence, can be used to fine-map translocation breakpoints rapidly. The application of CGH is limited to situations where there is a gain or loss of genetic material, which is not the case for truly balanced translocations. However, when genetic material from an unbalanced segregant is available, as in the present case, CGH can map breakpoints from the unbalanced translocation that can then be readily verified by FISH studies of the balanced translocation. We know of only one other case where an unbalanced meiotic segregant was used to map a constitutional balanced translocation breakpoint.²⁴

We studied a man with a *de novo* balanced 9;13 translocation, distal hypospadias, PAPVR and mild limb-length inequality. The chromosome 9 breakpoint fell in an intron of *BNC2*, a large (~470 kb) gene of unknown function with a highly complex pattern of alternative transcriptional processing. The chromosome 13 breakpoint fell in an intergenic region, ~400 kb 3' to the transcriptional unit of *LMO7*, a transcription factor gene. Targeted mutations of two other *LIM/PDZ* genes encoding actin-associated LIM protein or ZASP/Cypher/Oracle in mice have been found to cause congenital heart and muscle pathology.^{25,26} Expression of both *BNC2* and *LMO7* was enriched in human fetal heart and penis compared with other tissues. However, alteration of *LMO7* expression is unlikely to cause the observed phenotypes: the breakpoint was 3' of this gene, whereas long-range position effects are generally associated with breakpoints in 5' regulatory regions.²⁷ Also, roughly equal expression of both *LMO7* alleles was observed in the proband's lymphoblasts. *BNC2* also showed biallelic expression in the proband's lymphoblasts, as judged by RT-PCR and DNA sequencing. However, *BNC2* has a highly complex pattern of alternative transcriptional initiation, termination and splicing, with more than 90 000 different potential isoforms.¹² Because of limited informative expressed SNPs, we were unable to assay allelic expression of specifically those *BNC2* isoforms containing the last two exons most likely to be affected by the translocation. The translocation is predicted to result in a tail-to-tail orientation of *BNC2* exons 1–5




Figure 4 Urethral defects in *bnc2*^{+/-} and *bnc2*^{-/-} mice. (a) Gross appearance of external genitalia in newborn males and females (ventral view). In both male and female heterozygous newborns, a narrow epithelialized furrow because of incomplete closure of the urethral folds is visible. In the homozygous mutant the furrow is hypospadiac, with a wider and deeper groove than the hets and with a pit-like depression at the distal end. (b) Dye injection into the bladders of newborn males reveals defects in the penile urethral meatus of homozygotes.

Table 2 Frequency and types of urethral defects in *bnc2*^{+/-} and *bnc2*^{-/-} newborn mice

Genotype	N (%)	Males			Females			Males+Females				
		+	++	+++	+	++	+++	+	++	+++		
+/+	6 (75)	2 (25)	0 (0)	0 (0)	2 (50)	2 (50)	0 (0)	0 (0)	8 (67)	4 (33)	0 (0)	0 (0)
+/-	1 (6)	6 (35)	7 (41)	3 (18)	5 (29.5)	5 (29.5)	7 (41)	0 (0)	6 (18)	11 (32)	14 (41)	3 (9)
-/-	0 (0)	1 (11)	3 (33)	5 (56)	0 (0)	1 (11)	4 (44.5)	4 (44.5)	0 (0)	2 (11)	7 (40)	9 (50)

Abbreviations: N, normal; +, slight widening of urethral meatus; ++, epithelialized furrow in ventral midline of external genitalia; +++, wide nonepithelialized furrow. Total mice examined 64 (34 males and 30 females). Modal phenotype for each genotype shown in bold.

and *LMO7*, making a fusion transcript unlikely. As the expression level of *BNC2* in lymphoblastoid cells is so low (>40 cycles of amplification were required to obtain a detectable product for allelic expression assays), it is not feasible to determine whether there are any aberrant transcripts from the derivative chromosomes by techniques such as RT- or vectorette PCR. Tissues from the proband carrying the balanced translocation that express *BNC2* more strongly, for example, kidney, lung and prostate, were not available.

Altered *BNC2* transcription could be causally related to the proband's birth defects or coincidental. We sequenced the major coding

exons of *BNC2* in 40 subjects with APVR plus the proband, 48 subjects with hypospadias, and 23 controls with anatomically normal penile urethras. Missense mutations were identified in all three groups. Variants predicted by SIFT to be deleterious were present in three hypospadias subjects but also one control. The accuracy of SIFT is limited; other computational prediction programs, for example, Polyphen, add little value in the absence of structural information.²² Determining the significance of these mutations will require an assay for *BNC2* function, which currently does not exist. Larger numbers of subjects need to be screened, but the data indicate that *BNC2*

mutations do not account for a large percentage of APVR or hypospadias.

In order to corroborate a role for *BNC2* disruption in the proband's birth defects, we then examined *bnc2*^{-/-} and *bnc2*^{+/-} mice. No cardiovascular abnormalities were seen. Penile size was normal, suggesting normal androgen signaling in males, but both male and female homozygous mice showed a high incidence of distal urethral defects, with reduced penetrance in heterozygotes. As *Bnc2* is strongly expressed in the preputial lamella and mesenchymal cells surrounding the developing os penis and urethral corpus spongiosum, the protein may act on the closure of the urethral folds. *Bnc2* has been shown to be required for adequate multiplication of the palatal mesenchymal cells, and absence of *bnc2* causes cleft palate. Presumably *Bnc2* is essential for proper growth of periurethral mesenchymal cells, as it is for the palatal mesenchyme.²¹

Although different assays were used, *BNC2/Bnc2* expression was detected in human but not mouse fetal heart. Early events in pulmonary vein development are very similar between humans and mouse, but the adult anatomy of the mouse pulmonary veins differs from those in humans. In the mouse, the left and right pulmonary veins come together and drain into the left atrium as a single vein, whereas in humans four veins separately enter the right atrium after intussusception of the common pulmonary vein, which makes up part of the left atrium wall.^{28,29} This difference may explain why no PAPVR is seen in *Bnc2*-mutant mice and could suggest that the mechanism of PAPVR (which is totally unknown) may involve defects in this intussusception process.

In summary, we used a novel CGH-based approach to facilitate mapping of a balanced translocation associated with PAPVR and hypospadias. The translocation disrupted *BNC2*, a large, complex gene of unknown function whose expression is enriched in fetal heart and penis. The phenotype of *Bnc2*^{-/-} mice corroborated a role for *BNC2* in urethral development. Unlike previously identified male-specific hypospadias genes, *BNC2* appears to act locally in urethral development in both sexes. Further studies are needed to determine the relationship of *BNC2* expression to androgen signaling in males.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

Human studies were funded by a UT Southwestern High Risk/High Impact grant (ARZ), NIH R01 DK59164 (LAB), and Children's Medical Center at Dallas CCRAC Grant #2006-92 (LAB). Mouse studies were funded by the Association pour la Recherche sur le Cancer and the Ligue contre le Cancer (PD).

1 Gallentine ML, Morey AF, Thompson Jr IM: Hypospadias. a contemporary epidemiologic assessment. *Urology* 2001; **57**: 788–790.

2 Fredell L, Iselius L, Collins A *et al*. Complex segregation analysis of hypospadias. *Hum Genet* 2002; **111**: 231–234.

3 Page LA: Inheritance of uncomplicated hypospadias. *Pediatrics* 1979; **63**: 788–790.

- 4 Kalfa N, Sultan C, Baskin LS: Hypospadias: etiology and current research. *Urol Clin North Am* 2010; **37**: 159–166.
- 5 Silver RI, Russell DW: 5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias. *J Urol* 1999; **162**: 1142–1145.
- 6 Allera A, Herbst MA, Griffin JE, Wilson JD, Schweikert HU, McPhaul MJ: Mutations of the androgen receptor coding sequence are infrequent in patients with isolated hypospadias. *J Clin Endocrinol Metab* 1995; **80**: 2697–2699.
- 7 Sutherland RW, Wiener JS, Hicks JP *et al*. Androgen receptor gene mutations are rarely associated with isolated penile hypospadias. *J Urol* 1996; **156**: 828–831.
- 8 Fukami M, Wada Y, Miyabayashi K *et al*. Cxorf6 is a causative gene for hypospadias. *Nat Genet* 2006; **38**: 1369–1371.
- 9 Fukami M, Wada Y, Okada M *et al*.: Mastermind-like domain-containing 1 (MAMLD1 or Cxorf6) transactivates the Hes3 promoter, augments testosterone production, and contains the SF1 target sequence. *J Biol Chem* 2008; **283**: 5525–5532.
- 10 Mortlock DP, Innis JW: Mutation of HOXA13 in hand-foot-genital syndrome. *Nat Genet* 1997; **15**: 179–180.
- 11 Frisen L, Lagerstedt K, Tapper-Persson M, Kockum I, Nordenskjold A: A novel duplication in the HOXA13 gene in a family with atypical hand-foot-genital syndrome. *J Med Genet* 2003; **40**: e49.
- 12 Vanhoutteghem A, Djian P: The human basonuclin 2 gene has the potential to generate nearly 90 000 mRNA isoforms encoding over 2000 different proteins. *Genomics* 2007; **89**: 44–58.
- 13 Romano RA, Li H, Tummala R, Maul R, Sinha S: Identification of Basonuclin2, a DNA-binding zinc-finger protein expressed in germ tissues and skin keratinocytes. *Genomics* 2004; **83**: 821–833.
- 14 Vanhoutteghem A, Djian P: Basonuclin 2: an extremely conserved homolog of the zinc finger protein basonuclin. *Proc Natl Acad Sci USA* 2004; **101**: 3468–3473.
- 15 Tseng H, Green H: Association of basonuclin with ability of keratinocytes to multiply and with absence of terminal differentiation. *J Cell Biol* 1994; **126**: 495–506.
- 16 Yang Z, Gallicano GI, Yu QC, Fuchs E: An unexpected localization of basonuclin in the centrosome, mitochondria, and acrosome of developing spermatids. *J Cell Biol* 1997; **137**: 657–669.
- 17 Tian Q, Kopf GS, Brown RS, Tseng H: Function of basonuclin in increasing transcription of the ribosomal RNA genes during mouse oogenesis. *Development* 2001; **128**: 407–416.
- 18 Iuchi S, Green H: Basonuclin, a zinc finger protein of keratinocytes and reproductive germ cells, binds to the rRNA gene promoter. *Proc Natl Acad Sci USA* 1999; **96**: 9628–9632.
- 19 Wang J, Zhang S, Schultz RM, Tseng H: Search for basonuclin target genes. *Biochem Biophys Res Commun* 2006; **348**: 1261–1271.
- 20 Vanhoutteghem A, Djian P: Basonuclins 1 and 2, whose genes share a common origin, are proteins with widely different properties and functions. *Proc Natl Acad Sci USA* 2006; **103**: 12423–12428.
- 21 Vanhoutteghem A, Maciejewski-Duval A, Bouche C *et al*. Basonuclin 2 has a function in the multiplication of embryonic craniofacial mesenchymal cells and is orthologous to disco proteins. *Proc Natl Acad Sci USA* 2009; **106**: 14432–14437.
- 22 Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009; **4**: 1073–1081.
- 23 Higgins AW, Alkuraya FS, Bosco AF *et al*. Characterization of apparently balanced chromosomal rearrangements from the developmental genome anatomy project. *Am J Hum Genet* 2008; **82**: 712–722.
- 24 Bernheim A, Toujani S, Guillaud-Bataille M *et al*. Intragenic breakpoints localized by array CGH in a t(2;6) familial translocation. *Cytogenet Genome Res* 2007; **119**: 185–190.
- 25 Nakagawa N, Hoshijima M, Oyasu M, Saito N, Tanizawa K, Kuroda S: ENH, containing PDZ and LIM domains, heart/skeletal muscle-specific protein, associates with cytoskeletal proteins through the PDZ domain. *Biochem Biophys Res Commun* 2000; **272**: 505–512.
- 26 Guy PM, Kenny DA, Gill GN: The PDZ domain of the LIM protein enigma binds to beta-tropomyosin. *Mol Biol Cell* 1999; **10**: 1973–1984.
- 27 Kleinjan DA, van Heyningen V: Long-range control of gene expression: emerging mechanisms and disruption in disease. *Am J Hum Genet* 2005; **76**: 8–32.
- 28 Bleyl SB, Saijoh Y, Bax NA *et al*. Dysregulation of the PDGFRA gene causes inflow tract anomalies including TAPVR: integrating evidence from human genetics and model organisms. *Hum Mol Genet* 2010; **19**: 1286–1301.
- 29 Webb S, Brown NA, Wessels A, Anderson RH: Development of the murine pulmonary vein and its relationship to the embryonic venous sinus. *Anat Rec* 1998; **250**: 325–334.
- 30 den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 2000; **15**: 7–12.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)